Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now [Yahoo! Finance]
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: Yahoo! Finance
The optimism, led by a solid fourth-quarter 2023 performance and its product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist. Over the past year, this currently Zacks Rank #3 (Hold) stock has lost 70.5% against the 10.1% growth of the industry. The S&P 500 rose 24.9% in the same time frame. The renowned global provider of sequencing systems has a market capitalization of $978 million. The company projects 10.4% growth for 2024 and expects to maintain a strong performance going forward. PacBio's earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average surprise of 13.1%. Image Source: Zacks Investment Research Let's delve deeper. Strategic Deals: We are optimistic about PacBio's robust growth opportunities, thanks to its slew of strategic deals over the past few months. In November 2023, the company announced the addition of two tertiary analysis partners to
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks [Yahoo! Finance]Yahoo! Finance
- Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- PacBio moved to Neutral at JPMorgan after guidance cut [Seeking Alpha]Seeking Alpha
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating.MarketBeat
PACB
Earnings
- 2/15/24 - Beat
PACB
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- PACB's page on the SEC website